MTOR and tuberous sclerosis: For TSC patients undergoing mTOR inhibitor therapy, SS-OCTA imaging of RAHs may further serve as a surrogate marker for systemic disease activity in TSC, where structural changes in TSC-related brain or renal lesions are slow to manifest, and frequent imaging (e.g., brain MRI) is often impractical.